Frontida BioPharm, a pharmaceutical contract development and manufacturing organization (CDMO) based in Philadelphia and Chicago areas, has launched its new Category 1 (CAT.ONE) in vitro testing and evaluation services to support development and regulatory approvals for abuse-deterrent formulations of pain management and Central Nervous System (CNS) targeted therapies.
Frontida BioPharm, a pharmaceutical contract development and manufacturing organization (CDMO) based in Philadelphia and Chicago areas, has launched its new Category 1 (CAT.ONE) in vitro testing and evaluation services to support development and regulatory approvals for abuse-deterrent formulations of pain management and Central Nervous System (CNS) targeted therapies.
Frontida BioPharm Inc., a pharmaceutical Contract Development and Manufacturing Organization based in the Philadelphia and Chicago areas, has appointed Puneet Sapra as its new chief financial officer. Sapra will be replacing Andrew Wang, who recently accepted the CFO role at Frontage Holdings Corp., a CRO based in the U.S. and China.
Frontida BioPharm, Inc., a minority-owned pharmaceutical contract development and manufacturing organization based in Philadelphia and Chicago areas, has appointed Steven Roese as Vice President of Quality. Mr. Roese joins Frontida with over 25 years of experience in quality operations and pharmaceutical industry management.
Frontida BioPharm, Inc., a minority-owned contract development and manufacturing organization (CDMO), has appointed Steven Roese as Vice President of Quality. Mr. Roese joins Frontida with over 25 years of experience in quality operations and pharmaceutical industry management.
Frontida BioPharm Inc. has completed a facility expansion to its oral solid dose manufacturing operations with the commissioning of a Highly Potent Compound Contract Manufacturing Suite. This addition features 1000 sq. ft of readily available, hazard-certified production space.